Spruce Biosciences (SPRB) Company Long-Term Loans and Borrowings

Spruce Biosciences, Inc. - graphic logo of issuer SPRB

This chart illustrates that the market value of Spruce Biosciences (SPRB) on the GURU.Markets platform currently stands at 0.01. Spruce Biosciences aims to secure a dominant position in the orphan segment by bringing tildacerfont to market to combat adrenocortical hyperplasia. The business relies on the creation of innovative small molecules through intensive R&D research. Patent protection of key developments creates a robust barrier, despite the volatility of profit expectations.

SPRB Spruce Biosciences, Inc.: Company Long-Term Debts in the range 07/04/2022 - 10/28/2026

Spruce Biosciences, Inc. - analytical breakdowns and key metrics (SPRB)

- price and consensus price forecast:
Stock Price sprucebiosciences.com|SPRB - Price Target Chart
- market capitalization data:
Market Value Spruce Biosciences|SPRB - Total Company Value
- book capitalization data:
Accounting Value per Share Spruce Biosciences|SPRB - Book Capitalization|Market Capitalization to Book Value Ratio sprucebiosciences.com|SPRB - Cumulative Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Spruce Biosciences|SPRB - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Spruce Biosciences Inc.|SPRB - Company Aggregate Debts|Debts to Book Value Spruce Biosciences|SPRB - Company Long-Term Liabilities|Amount of Current Liabilities Spruce Biosciences
Fundamental valuation:SPRB - sprucebiosciences.com
Manufactured products of Spruce Biosciences

Investors are assessing long-term risks by analyzing debt leverage amid tight US monetary policy. This indicator captures real leverage, allowing for a granular calculation of the portfolio's potential loss asymmetry. The trend of long-term borrowed funds on the chart reflects the overall financial burden of the business. For Spruce Biosciences (SPRB), low debt is critically important when calibrating Tildacerfont trial protocols. However, the absence of liabilities does not guarantee stability in the event of a decline in the operating margins of the R&D pipeline.

Competitors of Spruce Biosciences

ascendispharma.com - Company Long-Term Debts|Company Long-Term Debt Madrigal Pharmaceuticals, Inc. (MDGL)|CORT: Company Long-Term Loans and Borrowings|RYTM (Rhythm Pharmaceuticals Inc) - Company Long-Term Debt|Akero Corp (AKRO) - Company Long-Term Liabilities|MTSR (Metsera Inc) - Company Long-Term Debts|Company Long-Term Debts moonlaketx.com (MLTX)|Crinetics (CRNX) - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings NAMS (NewAmsterdam Pharma Company)|Soleno - Company Long-Term Debt|Company Long-Term Liabilities Amicus Corp FOLD|ETNB (89bio, Inc.) - Company Long-Term Debts|agios.com (AGIO) - Long-Term Debt|GPCR - Company Long-Term Liabilities|MiMedx Group Inc (MDXG) - Amount of Long-Term Liabilities|RZLT (Rezolute Corp) - Company Long-Term Debts|Company Long-Term Debts Lexicon Corp|Company Long-Term Debts MBX Biosciences Inc (MBX)|Company Long-Term Debt ALT (altimmune.com)|AARD: Company Long-Term Debt|Sagimet Biosciences, Inc. - Long-Term Debt|BIOA - Company Long-Term Debt|BMEA - Company Long-Term Debt|quincetx.com - Company Long-Term Debts|GUTS (fractyl.com) - Long-Term Debt Volume|VTVT: Company Long-Term Debt|Long-Term Debt Volume ATPC|Company Long-Term Debt PLUR (Pluri Inc.)|Company Long-Term Liabilities SYBX (synlogictx.com)|Company Long-Term Debt LPCN|Matinas BioPharma Holdings, Inc. - Long-Term Debt Volume|Company Long-Term Debt Galecto|CTCX: Long-Term Liabilities|Company Long-Term Debt Lumos Pharma Corp LUMO|Company Long-Term Loans and Borrowings Organovo Corp|RDUS (Radius Recycling, Inc.) - Company Long-Term Liabilities